Literature DB >> 11238516

A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.

A Odermatt1, B Dick, P Arnold, T Zaehner, V Plueschke, M N Deregibus, H Repetto, B M Frey, F J Frey, P Ferrari.   

Abstract

Renal 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) is an enzyme responsible for the peripheral inactivation of cortisol to cortisone in mineralocorticoid target tissues. Mutations in the gene encoding 11betaHSD2 cause the syndrome of apparent mineralocorticoid excess (AME), an autosomal recessive form of inherited hypertension, in which cortisol acts as a potent mineralocorticoid. The mutations reported to date have been confined to exons 3-5. Here, we describe two siblings, 1 and 2 yr old, who were diagnosed with hypokalemic hypertension and low plasma aldosterone and renin levels, indicating mineralocorticoid hypertension. Analysis of urinary steroid metabolites showed a markedly impaired metabolism of cortisol, with (tetrahydrocortisol + 5alpha-tetrahydrocortisol)/tetrahydrocortisone ratios of 40-60, and nearly absent urinary free cortisone. Although phenotypically normal, the heterozygous parents showed a disturbed cortisol metabolism. Genetic analysis of the HSD11B2 gene from the AME patients revealed the homozygous deletion of six nucleotides in exon 2 with the resultant loss of amino acids Leu(114) and Glu(115), representing the first alteration found in the cofactor-binding domain. The deletion mutant, expressed in HEK-293 cells, showed an approximately 20-fold lower maximum velocity but increased apparent affinity for cortisol and corticosterone. In contrast, two additionally constructed substitutions, Glu(115) to Gln or Lys, showed increased maximal velocity and apparent affinity for 11beta-hydroxyglucocorticoids. Functional analysis of wild-type and mutant proteins indicated that a disturbed conformation of the cofactor-binding domain, but not the missing negative charge of Glu(115), led to the observed decreased activity of the deletion mutant. Considered together, these findings provide evidence for a role of Glu(115) in determining cofactor-binding specificity of 11betaHSD2 and emphasize the importance of structure-function analysis to elucidate the molecular mechanism of AME.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238516     DOI: 10.1210/jcem.86.3.7334

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

1.  In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence.

Authors:  Jonathan R Manning; Matthew A Bailey; Dinesh C Soares; Donald R Dunbar; John J Mullins
Journal:  Physiol Genomics       Date:  2010-06-22       Impact factor: 3.107

2.  [Rare forms of hypertension : From pheochromocytoma to vasculitis].

Authors:  H Haller; F Limbourg; B M Schmidt; J Menne
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

3.  Aldosterone synthase C-344T, angiotensin II type 1 receptor A1166C and 11-β hydroxysteroid dehydrogenase G534A gene polymorphisms and essential hypertension in the population of Odisha, India.

Authors:  Manisha Patnaik; Pallabi Pati; Surendra N Swain; Manoj K Mohapatra; Bhagirathi Dwibedi; Shantanu K Kar; Manoranjan Ranjit
Journal:  J Genet       Date:  2014-12       Impact factor: 1.166

4.  Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17beta-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells.

Authors:  Daniel P Sherbet; Oleg L Guryev; Mahboubeh Papari-Zareei; Dario Mizrachi; Siayareh Rambally; Sharareh Akbar; Richard J Auchus
Journal:  Endocrinology       Date:  2009-06-25       Impact factor: 4.736

Review 5.  The interplay of renal potassium and sodium handling in blood pressure regulation: critical role of the WNK-SPAK-NCC pathway.

Authors:  Aihua Wu; Martin Wolley; Michael Stowasser
Journal:  J Hum Hypertens       Date:  2019-02-05       Impact factor: 3.012

Review 6.  11β-hydroxysteroid dehydrogenases: A growing multi-tasking family.

Authors:  Elise P Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Mol Cell Endocrinol       Date:  2021-02-17       Impact factor: 4.102

Review 7.  Gene mutations that promote adrenal aldosterone production, sodium retention, and hypertension.

Authors:  Andreas G Moraitis; William E Rainey; Richard J Auchus
Journal:  Appl Clin Genet       Date:  2013-12-24

8.  Herbal Medicine Containing Licorice May Be Contraindicated for a Patient with an HSD11B2 Mutation.

Authors:  Indra Sari Kusuma Harahap; Naoko Sasaki; Surini Yusoff; Myeong Jin Lee; Satoru Morikawa; Noriyuki Nishimura; Tomohiro Sasaki; Seiichiro Usuki; Midori Hirai; Mika Ohta; Yutaka Takaoka; Takashi Nishimoto; Hisahide Nishio
Journal:  Evid Based Complement Alternat Med       Date:  2011-02-20       Impact factor: 2.629

9.  Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia.

Authors:  Peng Fan; Yi-Ting Lu; Kun-Qi Yang; Di Zhang; Xue-Ying Liu; Tao Tian; Fang Luo; Lin-Ping Wang; Wen-Jun Ma; Ya-Xin Liu; Hui-Min Zhang; Lei Song; Jun Cai; Ying Lou; Xian-Liang Zhou
Journal:  Endocrine       Date:  2020-08-20       Impact factor: 3.633

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.